DLL-0018-A1-10ML

SP600125 Liposomes, Formulation HZ12

PEGylated liposomes containing JNK inhibitor SP600125 (Nsc75890). SP600125 is a reversible, ATP-competitive broad-spectrum JNK inhibitor (JNK1/JNK2, IC50 40 nM; JNK3, IC50 90 nM). with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase A，FLT3 and TRKA. SP600125 inhibits ferroptosis, autophagy, and activates apoptosis. SP600125 is insoluble in aqueous media. This product is a pre-formulated liposomal version of Sp600125 which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

3024.95 €

DLL-0005-A1-10ML

Adavosertib Liposomes, Formulation WD4

PEGylated liposomes containing Wee-1 kinase inhibitor adavosertib (MK1775; AZD1775), remote loaded by an ammonium sulfate gradient. The lipid composition of the liposomes is the same as Doxil. Sterile filtered and supplied ready for use in preclinical studies in rodents or in vitro. Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint and is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327. For preclinical research use only.

5044.95 €

DLL-0005-A1-2ML

Adavosertib Liposomes, Formulation WD4

PEGylated liposomes containing Wee-1 kinase inhibitor adavosertib (MK1775; AZD1775), remote loaded by an ammonium sulfate gradient. The lipid composition of the liposomes is the same as Doxil. Sterile filtered and supplied ready for use in preclinical studies in rodents or in vitro. Adavosertib is a potent, ATP-competitive Wee-1 kinase inhibitor, which hinders the G2 DNA damage response checkpoint and is reported to enhance cytotoxic effects of several compounds including 5-FU and NSC 613327. For preclinical research use only.

1004.95 €

FL-0001-10ML

DiR Labeled Tumor-Accumulating Liposomes™

Long-circulating, tumor-accumulating fluorescent liposomes (DiR-labeled). These fluorescent liposomes passively accumulate in solid tumor tissues for a variety of murine tumor models and are labeled with the fluorescent dye, DiR, making them excellent for in vivo and ex vivo imaging studies in rodents. The liposomes are compatible for use with PerkinElmer In Vivo Imaging Systems (IVIS) equipped with DiR filter set (DiR Absorption/Emission: 748/780; IVIS Filter Set: 710 ex/760 em [1]). PEGylated to improve stability, prolong circulation time and reduce reticuloendothelial system clearance for in vivo applications. The lipid composition is very similar to that of the well-characterized Doxil® formulation.

1913.95 €

FL-0001-2ML

DiR Labeled Tumor-Accumulating Liposomes™

Long-circulating, tumor-accumulating fluorescent liposomes (DiR-labeled). These fluorescent liposomes passively accumulate in solid tumor tissues for a variety of murine tumor models and are labeled with the fluorescent dye, DiR, making them excellent for in vivo and ex vivo imaging studies in rodents. The liposomes are compatible for use with PerkinElmer In Vivo Imaging Systems (IVIS) equipped with DiR filter set (DiR Absorption/Emission: 748/780; IVIS Filter Set: 710 ex/760 em [1]). PEGylated to improve stability, prolong circulation time and reduce reticuloendothelial system clearance for in vivo applications. The lipid composition is very similar to that of the well-characterized Doxil® formulation.

701.95 €

cAP-09B

Pericyte Growth Medium (Super Rich Formulation)

473.96 €